Sharene Watsen, PA
Payments from drug & device makers
What this record shows
16 manufacturers reported payments, led by Insulet Corporation at 40.3% of the total. 2025 is the largest year on record at $4,882, more than ten times the $310 reported in 2021. Among medical clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $87.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$3K
- Medtronic$2K
- Abbott$574
- Amgen$371
- Tandem Diabetes Care, Inc.$371
- Ascendis Pharma Endocrinology Inc$113
- plus $435 from 10 others
What the payments were for
- Travel & lodging$3,58552%
- Food & beverage$3,30948%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 19 | $2,775 |
| Medtronic | 20 | $2,254 |
| Abbott | 13 | $574 |
| Amgen(2 entities) | 5 | $371 |
| Tandem Diabetes Care, Inc. | 7 | $371 |
| Ascendis Pharma Endocrinology Inc | 1 | $113 |
| Corcept Therapeutics | 1 | $109 |
| Bayer | 1 | $90 |
| Novo Nordisk | 3 | $46 |
| Lilly USA, LLC | 3 | $42 |
| Dexcom, Inc. | 1 | $41 |
| Averitas Pharma Inc. | 1 | $33 |
| BETA Bionics, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| IBSA Pharma Inc. | 1 | $20 |
| AstraZeneca | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$2,379
- MINIMED 780G$895
- InPen$160
- FREESTYLE LIBRE 3$158
- FreeStyle Libre$142
- EVENITY$129
- t:slim X2 Insulin Pump with Control-IQ$114
- Yorvipath$113
- Korlym$109
- TEPEZZA$105
- Prolia$102
How this compares
$6,894 in reported general payments places this provider in the 95th percentile of 265 medical providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $129,070 |
| TrulicityDulaglutide | 66 | $85,398 |
| TymlosAbaloparatide | 29 | $70,457 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $45,566 |
| FarxigaDapagliflozin Propanediol | 38 | $45,223 |
| MounjaroTirzepatide | 37 | $41,678 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $41,297 |
| JardianceEmpagliflozin | 25 | $35,617 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $31,423 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $30,385 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $25,599 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $20,041 |
| HumalogInsulin Lispro | 45 | $15,752 |
| NovologInsulin Aspart | 33 | $12,191 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 16 | $7,829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro, Baqsimi | $42 | $153,273201 claims |
| Novo NordiskOzempic, Novolog | $46 | $141,261142 claims |
| AstraZenecaFarxiga | $11 | $45,22338 claims |
| IBSA Pharma Inc.Tirosint-Sol | $20 | $5,59415 claims |
| Sanofi-aventis U.S. LLCLantus | $20 | $1,64712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 265 medical providers in Idaho.
Other medical in Boise
- Jessica BishopBoise$60K
- Cali BradberryBoise$9K
- Zana DelicBoise$4K
- Jacob TebbsBoise$3K
- Ronnie IsaacsonBoise$3K
- Scott AstleyBoise$3K
- Shawna BeechinorBoise$2K
- Melissa KroonBoise$2K
- Dillon SmithBoise$2K
- Jessie ZimmermanBoise$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.